Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Announces Management Change
NEWTON, Mass. , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Mike Falvey , Executive Vice President, Chief Financial Officer and Treasurer, intends  to leave the company to pursue other interests.   Mr.
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes
NEWTON, Mass. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “Notes”).  The Notes will be sold in a
View HTML
Toggle Summary Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes
NEWTON, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of convertible senior notes due 2025 (the
View HTML
Toggle Summary U.S. Food and Drug Administration Accepts Karyopharm’s New Drug Application for Selinexor and Grants Priority Review
--  Application Seeks Accelerated Approval for Selinexor as a Treatment for Patients with Penta-Refractory Multiple Myeloma  -- --  PDUFA Date Set for April 6, 2019  -- NEWTON, Mass. , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 108,900 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm to Participate in Upcoming Investor Conferences
NEWTON, Mass. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:  The Cantor Fitzgerald Global
View HTML
Toggle Summary Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology
-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma -- -- One Poster Presentation Featuring Previously Reported Phase 1b/2
View HTML
Toggle Summary Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting
-- Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle (4 Weeks) of Treatment -- --  Median Survival of 8.6 Months in All Patients; Median Survival of 15.6 Months in Patients with MR or
View HTML
Toggle Summary Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEWTON, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 62,500 shares of Karyopharm’s
View HTML
Toggle Summary Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors
-- Current Chief Executive Officer of Abeona Therapeutics, Inc. and former Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc. ; Brings Wealth of Leadership and Global Strategic Experience -- NEWTON, Mass. , Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm
View HTML